With Pipeline of Syndromic Tests, Qorvo Eyes Emergence as More Than a COVID Company
Article By Greg Cima / April 25, 2023
Qorvo Biotechnologies said it is closing in on the launch of its point-of-care COVID-19 and influenza test as the firm works to expand its menu beyond COVID-19 and into syndromic panels and cardiac disease tests.
News
Outcome Capital Launches Dedicated Healthcare Services Practice to Expand Strategic Advisory and Investment Banking Capabilities
BOSTON–(BUSINESS WIRE)–Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced the launch of its Healthcare Services Practice, expanding the firm’s strategic and transactional advisory capabilities to meet the needs of companies operating across the rapidly evolving healthcare services sector. “Establishing a dedicated Healthcare Services Practice allows us to […]
Read MoreResources
Outcome Capital Life Science Market Pulse, September 2025
Outcome Capital Life Science Market Pulse September 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
